Literature DB >> 30179966

CORR Insights®: Should the Use of Biologic Agents in Patients With Renal and Lung Cancer Affect Our Surgical Management of Femoral Metastases?

Adam S Levin1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30179966      PMCID: PMC6437379          DOI: 10.1097/CORR.0000000000000479

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


× No keyword cloud information.
  12 in total

1.  Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial.

Authors:  Andrew J Armstrong; Susan Halabi; Tim Eisen; Samuel Broderick; Walter M Stadler; Robert J Jones; Jorge A Garcia; Ulka N Vaishampayan; Joel Picus; Robert E Hawkins; John D Hainsworth; Christian K Kollmannsberger; Theodore F Logan; Igor Puzanov; Lisa M Pickering; Christopher W Ryan; Andrew Protheroe; Christine M Lusk; Sadie Oberg; Daniel J George
Journal:  Lancet Oncol       Date:  2016-01-13       Impact factor: 41.316

2.  Patient survival after surgery for osseous metastases from renal cell carcinoma.

Authors:  Patrick P Lin; Attiqa N Mirza; Valerae O Lewis; Christopher P Cannon; Shi-Ming Tu; Nizar M Tannir; Alan W Yasko
Journal:  J Bone Joint Surg Am       Date:  2007-08       Impact factor: 5.284

3.  Should the Use of Biologic Agents in Patients With Renal and Lung Cancer Affect Our Surgical Management of Femoral Metastases?

Authors:  Christina J Gutowski; Benjamin Zmistowski; Nicola Fabbri; Patrick J Boland; John H Healey
Journal:  Clin Orthop Relat Res       Date:  2019-04       Impact factor: 4.176

4.  Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study.

Authors:  Patrick A Ott; Elena Elez; Sandrine Hiret; Dong-Wan Kim; Anne Morosky; Sanatan Saraf; Bilal Piperdi; Janice M Mehnert
Journal:  J Clin Oncol       Date:  2017-08-16       Impact factor: 44.544

5.  The revised Tokuhashi score; analysis of parameters and assessment of its accuracy in determining survival in patients afflicted with spinal metastasis.

Authors:  A Aoude; M Fortin; Sulta Aldebeyan; J Ouellet; L P Amiot; M H Weber; P Jarzem
Journal:  Eur Spine J       Date:  2016-12-23       Impact factor: 3.134

6.  Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.

Authors:  Martin Reck; Delvys Rodríguez-Abreu; Andrew G Robinson; Rina Hui; Tibor Csőszi; Andrea Fülöp; Maya Gottfried; Nir Peled; Ali Tafreshi; Sinead Cuffe; Mary O'Brien; Suman Rao; Katsuyuki Hotta; Melanie A Leiby; Gregory M Lubiniecki; Yue Shentu; Reshma Rangwala; Julie R Brahmer
Journal:  N Engl J Med       Date:  2016-10-08       Impact factor: 91.245

7.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).

Authors:  E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij
Journal:  Eur J Cancer       Date:  2009-01       Impact factor: 9.162

8.  Survival outcomes for advanced kidney cancer patients in the era of targeted therapies.

Authors:  Arpit Rao; Charles Wiggins; Richard C Lauer
Journal:  Ann Transl Med       Date:  2018-05

9.  Estimating survival in patients with operable skeletal metastases: an application of a bayesian belief network.

Authors:  Jonathan Agner Forsberg; John Eberhardt; Patrick J Boland; Rikard Wedin; John H Healey
Journal:  PLoS One       Date:  2011-05-13       Impact factor: 3.240

10.  Tumour response interpretation with new tumour response criteria vs the World Health Organisation criteria in patients with bone-only metastatic breast cancer.

Authors:  T Hamaoka; C M Costelloe; J E Madewell; P Liu; D A Berry; R Islam; R L Theriault; G N Hortobagyi; N T Ueno
Journal:  Br J Cancer       Date:  2010-01-26       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.